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Abstract
Our previous microarray study showed that the non-specific cytotoxic cell receptor protein 1 (Nccrp1) transcript is
significantly upregulated in the gastric mucosa of carbonic anhydrase IX (CA IX)-deficient (Car92/2) mice. In this paper, we
aimed to characterize human NCCRP1 and to elucidate its relationship to CA IX. Recombinant NCCRP1 protein was
expressed in Escherichia coli, and a novel polyclonal antiserum was raised against the purified full-length protein.
Immunocytochemistry showed that NCCRP1 is expressed intracellularly, even though it has previously been described as a
transmembrane protein. Using bioinformatic analyses, we identified orthologs of NCCRP1 in 35 vertebrate genomes, and up
to five paralogs per genome. These paralogs are FBXO genes whose protein products are components of the E3 ubiquitin
ligase complexes. NCCRP1 proteins have no signal peptides or transmembrane domains. NCCRP1 has mainly been studied
in fish and was thought to be responsible for the cytolytic function of nonspecific cytotoxic cells (NCCs). Our analyses
showed that in humans, NCCRP1 mRNA is expressed in tissues containing squamous epithelium, whereas it shows a more
ubiquitous tissue expression pattern in mice. Neither human nor mouse NCCRP1 expression is specific to immune tissues.
Silencing CA9 using siRNAs did not affect NCCRP1 levels, indicating that its expression is not directly regulated by CA9.
Interestingly, silencing NCCRP1 caused a statistically significant decrease in the growth of HeLa cells. These studies provide
ample evidence that the current name, ‘‘non-specific cytotoxic cell receptor protein 1,’’ is not appropriate. We therefore
propose that the gene name be changed to FBXO50.
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Introduction
Carbonic anhydrase IX (CA IX) belongs to a family of
mammalian a-carbonic anhydrases (CAs), zinc-containing metal-
loenzymes that catalyze the reversible hydration of carbon dioxide
in the reaction CO2+H2O«H++HCO32. CA IX is a dimeric
transmembrane protein that has many unique features that
distinguish it from other CAs [1,2]. First, the expression of CA
IX is limited to a few cell types in normal tissues, but it is highly
expressed in several tumors, especially under hypoxic conditions.
Furthermore, CA IX is involved in the regulation of tumor pH
which makes it an attractive antitumor drug target [3]. Second,
CA IX is the only member of the CA family that has a
proteoglycan (PG) domain, which may contribute to cell adhesion,
in addition to a catalytic CA domain [4]. Third, CA IX has a role
in cell proliferation; this was demonstrated by the generation of
CA IX knockout mice [5]. These mice showed gastric hyperplasia
of the glandular epithelium with numerous cysts. In a recent study,
we investigated the effect of CA IX deficiency on whole-genome
gene expression in gastric mucosa using microarrays [6]. Several
candidate genes were identified whose altered expression could
explain the abnormal cell lineage phenotype in Car92/2 gastric
mucosa. In subsequent studies, we focused on three poorly
characterized genes that have only been the subject of a few
published reports. One of these genes, non-specific cytotoxic cell
receptor protein 1 (Nccrp1), was significantly overexpressed in
Car92/2 gastric mucosa compared with wild-type mice.
NCCRP1 has been predicted to be a type II [7] or type III [8]
membrane protein and has been cloned from catfish, zebrafish,
tilapia, gilthead seabream and carp [7–12]. NCCRP1 is believed
to be a receptor expressed in nonspecific cytotoxic cells (NCCs)
that is responsible for their cytolytic function and has been
suggested to consist of three domains [13].
An interesting feature of the fish NCCRP1 proteins is their
homology with the F-box-only proteins. The zebrafish and catfish
NCCRP1 proteins share approximately 30% identity with this
subset of the F-box superfamily of proteins [12]. The homology is
considered to be restricted to an F-box-associated (FBA) domain
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located in the C terminus, as fish NCCRP1 proteins are thought to
lack the F-box motif in their N-termini. However, our analyses of
its sequence and structure indicate the presence of a shorter
version of the F-box domain in NCCRP1 proteins in mammals
and possibly even in fish. The function of the F-box is to mediate
protein-protein interactions, and F-box proteins are known to bind
protein substrates for ubiquitin-mediated proteolysis [14]. F-box
proteins recognize various substrates, but only members of the
FBXO subfamily have the ability to bind glycoproteins [15].
The tissue distribution of Nccrp1 mRNA has been studied in
several fish species, and its expression was found to be ubiquitous. In
tilapia, Nccrp1 is expressed in all immune and non-immune tissues
[9]. The relative expression level was highest in the liver, followed
by the head, kidney, spleen and intestine. Lower levels were
detected in the brain, gill and heart. Nccrp1 expression was lowest in
the skin. Similarly, constitutive expression of Nccrp1 transcripts was
detected in gilthead seabream [10] and carp [11]. Nccrp1 mRNA
expression has also been studied in the tetrapod animal axolotl [16].
Nccrp1 transcripts were detected in many tissues, including the limb
blastema, normal limb, skin, lung and spleen, but not in the brain or
liver. High mRNA levels were detected in the spleen and
regeneration blastema and in isolated blood cells.
To the best of our knowledge, this is the first study to
characterize human NCCRP1. We expressed this gene in E. coli
and analyzed its structure using biochemical methods. We also
examined the expression of NCCRP1 mRNA in human and mouse
tissues. Furthermore, we have investigated the association between
NCCRP1 and CA IX using siRNA technology. Our experimental
and bioinformatics results contradict the previous prediction that
the NCCRP1 protein is localized to the plasma membrane and
point unambiguously to its function as a protein-binding F-box
component of E3 ubiquitin ligases in the cytoplasm.
Results
Comparison of NCCRP1 and FBXO sequences
An ortholog of NCCRP1 was identified in 35 vertebrate genomes
from Ensembl ortholog tables. In fugu (Takifugu rubripes), two
orthologs were found. We found 21 protein sequences from 20
species to be at least 90% complete. Table 1 shows the Ensembl
gene identifiers for all identified orthologs, with the 20 species used
in further bioinformatic analyses in bold.
Multiple sequence alignment of 21 NCCRP1 proteins in Fig. 1
shows that the mouse and rat sequences in Ensembl are either 25
residues longer at the N-terminus, or the real start codon is the one
corresponding to M26. Mammalian sequences are characterized
by a proline-rich N-terminal domain of approximately 60 residues,
whereas fish sequences show shorter insertions around columns
150 and 190 in the alignment. NCCRP1 from the frog X. tropicalis
has short insertions similar to the fish sequences, but the N-
terminus is incomplete, so the presence of the N-terminal domain
remains inconclusive.
A major portion of the N-terminal domain in mammals is
predicted to be disordered. Prediction analysis of the human,
mouse and wallaby sequences yielded disordered domains of 70,
57 and 49 residues, respectively. These regions are underlined in
Fig. 1, which shows the end point of the disordered regions to be
very close to the end of the additional sequence seen in mammals.
There is an analogous Glu- and Ala-rich N-terminal domain in the
PEST domain of FBXO2 that also seems to be disordered. The N-
terminal 47 residues show no electron density in the crystal
structures of mouse FBXO2 (2E31, 2E32, 2E33) [17], and the
disorder prediction is consistent with the 41 N-terminal residues
predicted to be disordered.
The human paralogs of NCCRP1, as shown by the Ensembl
comparative genomics tools and Blast searches, are the genes
FBXO2, FBXO6, FBXO17, FBXO27 and FBXO44. The protein
products of these five genes are components of E3 ubiquitin ligase
complexes, and they define a lectin subfamily of ubiquitin ligases
[15]. In humans, the genes FBXO2, FBXO6 and FBXO44 are
contiguous genes on chromosome 1 (at 11.70 to 11.74 Mb), and
FBXO17, FBXO27 and NCCRP1 are on chromosome 19 (at 39.4 to
39.7 Mb). The protein sequence identity of NCCRP1 with the
other five lectin-type FBXO proteins ranges from 31% to 36% in
the last 180 residues, and the Blast E values range from 10227 to
10218, clearly indicating that these proteins share homology and
common ancestry.
Table 1. NCCRP1 orthologs found in Ensembl genomes.*
Species Ensembl Gene ID
Anole Lizard (Anolis carolinensis) ENSACAG00000011950
Armadillo (Dasypus novemcinctus) ENSDNOG00000018735
Bushbaby (Otolemur garnettii) ENSOGAG00000012185
Cat (Felis catus) ENSFCAG00000007425
Chimpanzee (Pan troglodytes) ENSPTRG00000010953
Cow (Bos taurus) ENSBTAG00000014296
Dog (Canis familiaris) ENSCAFG00000005593
Dolphin (Tursiops truncatus) ENSTTRG00000014969
Elephant (Loxodonta africana) ENSLAFG00000026532
Fugu (Takifugu rubripes) (1 of 2) ENSTRUG00000006309
Fugu (Takifugu rubripes) (2 of 2) ENSTRUG00000013740
Gibbon (Nomascus leucogenys) ENSNLEG00000014516
Gorilla (Gorilla gorilla) ENSGGOG00000028030
Guinea Pig (Cavia porcellus) ENSCPOG00000009451
Hedgehog (Erinaceus europaeus) ENSEEUG00000015408
Horse (Equus caballus) ENSECAG00000018954
Human (Homo sapiens) ENSG00000188505
Hyrax (Procavia capensis) ENSPCAG00000004015
Kangaroo rat (Dipodomys ordii) ENSDORG00000001051
Macaque (Macaca mulatta) ENSMMUG00000013906
Marmoset (Callithrix jacchus) ENSCJAG00000014055
Medaka (Oryzias latipes) ENSORLG00000000459
Microbat (Myotis lucifugus) ENSMLUG00000002162
Mouse (Mus musculus) ENSMUSG00000047586
Opossum (Monodelphis domestica) ENSMODG00000013456
Orangutan (Pongo abelii) ENSPPYG00000009956
Panda (Ailuropoda melanoleuca) ENSAMEG00000008646
Pika (Ochotona princeps) ENSOPRG00000006693
Platypus (Ornithorhynchus anatinus) ENSOANG00000015297
Rabbit (Oryctolagus cuniculus) ENSOCUG00000011658
Rat (Rattus norvegicus) ENSRNOG00000026244
Stickleback (Gasterosteus aculeatus) ENSGACG00000020167
Tetraodon (Tetraodon nigroviridis) ENSTNIG00000006031
Wallaby (Macropus eugenii) ENSMEUG00000001939
Xenopus tropicalis ENSXETG00000005319
Zebrafish (Danio rerio) ENSDARG00000035326
*Twenty-one genes with at least 90% complete predicted protein products are
shown in boldface.
doi:10.1371/journal.pone.0027152.t001
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In the available fish genomes, we only found orthologs to
FBXO2, FBXO44 and NCCRP1. Interestingly, the zebrafish
genome carries a cluster of ten copies of FBXO44 orthologs on
chromosome 23.
Analysis of protein domains
By Interpro scan, all 21 protein sequences had domain matches
to ‘‘Fbox-associated’’ (FBA, IPR007397) and ‘‘galactose-binding
domain-like’’ (IPR008979) patterns in the ,200 C-terminal
residues in fish and frog species and ,180 residues in mammalian
species. Only the protein products of NCCRP1 and the above five
FBXO gene loci are annotated to contain an FBA domain (InterPro
entry IPR007397), and no other human proteins were found in
Blast searches when NCCRP1 or the FBA domain of FBXO2 were
used as queries. The products of these five human FBXO genes also
contain a cyclin-like F-box domain pattern (InterPro entry
IPR001810) in the N-terminal region that spans 50 residues or
less, but none of the NCCRP1 proteins match this pattern.
Fig. 2 shows the alignment of human NCCRP1 with these five
FBXO proteins and their phylogenetic tree. Although there was
no match to the cyclin-like F-box domain pattern in the NCCRP1
sequence, 12 residues are conserved between human NCCRP1
and at least three other FBXO proteins within the F-box domain
region (lines on top of the alignment in Fig. 2). The main
differences in this region are found in three indels, in which
NCCRP1 has shorter sequences and lacks many conserved
residues, most notably the signature pattern CRxVC. To test
whether these deletions would be compatible with the F-box
domain structure, we visualized them in the known 3D structure of
mouse FBXO2 [17].
Fig. 3 shows the sequences to be deleted in purple. They
constitute one complete helical turn in alpha helix a1 (helices
named as described previously [17]), one helix turn in a2 and part
of the a29 loop, the end of helix a4, and the major part of the
linker before a5, including the flexible residues 104 to 108 that are
missing from the structure between the open ends (purple and
cyan). These deletions could be modeled in a shorter version of the
F-box fold while retaining the positions of a3 and a4 and the
sugar-binding domain (SBD), as in the structure 2E31 in PDB, by
linking a5 to the truncated a4 and shifting the right-hand ends of
helices a1 and a2 to the left. Alternatively, the SBD could be
moved to bring a5 into the position of a4, which would still
maintain the relative orientation between the F-box and the SBD.
Fig. 1 shows the extent of the F-box domain in these two models.
The solid line over the alignment indicates the version in which a4
is truncated, whereas the dotted line indicates the fusion of a5 into
the F-box domain. In conclusion, we believe that the region
preceding the SBD in human and other mammalian NCCRP1
proteins is indeed folded as an F-box domain.
In fish NCCRP1 sequences, the F-box domain is not detected
(by matching to the F-box pattern in InterPro), which is not
surprising because the fish sequences start in the middle of the F-
box region (Fig. 1). However, because the fish sequences only lack
six residues or less from the beginning of the structurally defined F-
box domain (see line at the top of the alignment in Fig. 1), a
version with a shortened initial helix a1 might exist. This remains
speculative because the fish and mammalian sequences are not
highly conserved in the putative F-box region.
TMHMM predicted that there are no transmembrane helices in
any of the studied 21 NCCRP1 ortholog proteins. SignalP
predicted no signal peptides in any of the proteins, and TargetP
predicted a non-mitochondrial, non-secreted localization for all
proteins. The predictions for the mouse and rat sequences were
run with alternative start sites: residue 1, as in Ensembl proteins,
and residue 26, consistent with the translation start site of other
mammalian sequences. All of these results indicate the absence
of transmembrane domains and cytoplasmic localization of
NCCRP1 in all of the studied species.
Jaso-Friedmann et al. [12] reported Box-1 motifs in zebrafish
and catfish NCCRP1 proteins. We did not detect these motifs in
the NCCRP1 proteins we analyzed, and we disagree with their
finding because they took the liberty of reversing the sequences,
which does not make sense for peptides.
Modelling of suggested active peptides
Because the NCCRP1 proteins could not be located on the cell
surface, as would be expected for the proteins to function as
antigen receptors [7], we next asked whether there were any
structural explanations for the previously reported [8,12] cytotox-
icity-inhibiting activity of NCCRP1-derived peptides (a more
potent 16-mer and a less potent 37-mer). The location of these two
overlapping peptides is shown under the alignment in Fig. 1. Fig. 4
shows the location of the 16-mer in yellow and the 37-mer in
yellow plus blue, extrapolated into the structure of mouse FBXO2
based on the sequence alignment. These peptides contain long
beta-strand elements coming from the amphiphilic beta sheets,
which have one side of mainly hydrophobic residues (facing the
protein core). Randomized peptides with same residues would be
highly unlikely to have such an organized amphiphilic surface.
Production, purification and characterization of
recombinant human NCCRP1
The human NCCRP1 cDNA was cloned into the expression
vector pGEX-4T-1 and expressed as a fusion protein with GST.
The recombinant NCCRP1 protein was characterized using SDS-
PAGE based on its apparent size. After purification by affinity
chromatography and digestion with thrombin, NCCRP1 ap-
peared as polypeptide of approximately 30 kDa after SDS-PAGE
(Fig. 5, lane 1). Fig. 5 also shows the 26-kDa GST band (lane 2).
Western blotting was used to confirm the reactivity of the
antibody produced against NCCRP1. Fig. 6 shows a single band
for NCCRP1 in lane 1, whereas the control blot using normal
rabbit serum was negative (Fig. 6, lane 2).
Mass spectrometry
Upon buffer exchange, the NCCRP1 protein sample slightly
precipitated, and therefore, mass analyses were conducted from
both the precipitate and supernatant. A small amount of the
precipitate was dissolved in 100 ml of 10 mM ammonium
bicarbonate buffer, pH 8.5, further diluted with acetonitrile/
water/acetic acid (49.5:49.5:1.0, v/v) mixture and directly analyzed
with ESI FT-ICR mass spectrometry. From this analysis, the
Figure 1. Alignment of 21 NCCRP1 protein sequences from 20 species. Shading indicates conservation, with more strongly conserved
positions shaded in darker colors. Uppercase letters under the alignment give the identity of fully conserved residues, and lowercase letters show the
consensus residue of partially conserved positions. Underlined sequences in the N-terminal region are predicted to be disordered in the three species
studied. The line over the sequence (columns 85 to 123) indicates the predicted F-box domain. The solid line (cols. 85 to 113) indicates an alternative
model (see ‘‘Analysis of protein domains’’). Underlining of the bottom consensus line indicates the location of the peptides discussed in ‘‘Modeling of
suggested active peptides’’ and studied in previous work [8]. Solid line: 16-mer peptide; Solid line plus dotted line: 37-mer peptide.
doi:10.1371/journal.pone.0027152.g001
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Figure 2. Alignment of human NCCRP1 with its closest five paralogs and their phylogenetic tree. (A) Shading and consensus lettering
were used as described in Fig. 1. Dotted line over the sequence: F-box domain, cyclin-like, as defined in human FBXO2 by InterPro. Solid line over the
sequence: F-box domain as defined by compact alpha-helical folding in PDB entry 2E31 [17]. Line under the sequence: the sugar-binding domain as
defined previously [17]. (B) Phylogenetic tree with bootstrap support percentages for each node.
doi:10.1371/journal.pone.0027152.g002
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precipitate was found to contain a 27-kDa protein as well as a small
3-kDa peptide (Fig. 7A). The most abundant isotopic mass of the
protein (27743.57 Da) was matched against the NCCRP1 sequence
and a reasonable match was found with the fragment containing
residues 31–275 (theoretically 27743.45 Da), indicating the pres-
ence of one intra-molecular disulfide (Cys158-Cys192) in the
protein structure (see inset in Figure 7A). The monoisotopic mass
of the observed peptide P (3260.51 Da) was also matched against
the NCCRP1 sequence, and it was found to correspond to the first
30 residues of NCCRP1 with an additional Gly-Ser in the N-
terminus (theoretically 3260.52 Da). These amino acids are
attributable to the pGEX-4T-1 expression vector construct (Fig. 7B).
To further identify the produced protein, a database search for
the trypsin-digested protein was performed. An aliquot of 20 ml of
the tryptic digest sample was further diluted with 150 ml of an
acetonitrile/water/acetic acid (49.5:49.5:1.0, v/v) mixture and
analyzed directly. The digestion resulted in 18 identified tryptic
peptides within an average mass error of 6 ppm, covering 75% of
the NCCRP1 sequence. A search against the SwissProt database
gave an unambiguous hit for human NCCRP1 (NCRP1_HU-
MAN) with a Mowse score of 370 (Figure S1).
Figure 3. Structure of mouse FBXO2 (cyan) complexed with SKP1 (yellow). PDB entry 2E31 [17]. The regions of FBXO2 shown in purple
correspond to parts that would be deleted from a model of the F-box domain of human NCCRP1. The first 46 residues and residues 104–108 of
FBXO2 are not resolved in the structure. The sugar-binding site (SBD) is at the extreme right in this image. Alpha helices of FBXO2 are labeled at the
N-end of each helix, as described previously [17].
doi:10.1371/journal.pone.0027152.g003
Figure 4. Structure of the sugar-binding domain of mouse
FBXO2 complexed with an oligosaccharide of bovine ribonu-
clease A. PDB entry 2E33 [17]. Two views rotated 180 degrees vertically
are shown. The protein part of ribonuclease A is omitted. The coloring
indicates the positions homologous to the NCCRP1 peptides discussed
in ‘‘Modeling of suggested active peptides’’ and studied in previous
work [8,13]. Yellow: 16-mer peptide; yellow plus blue: 37-mer peptide.
doi:10.1371/journal.pone.0027152.g004
Figure 5. SDS-PAGE of the human recombinant NCCRP1
protein produced in E. coli. Lane 1 shows the 30-kDa NCCRP1
eluted from the affinity chromatography column after thrombin
treatment. In lane 2, 26-kDa GST is shown.
doi:10.1371/journal.pone.0027152.g005
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Mass spectra measured from the supernatant instead revealed
the same 3-kDa peptide that was detected from the precipitate as
well as a small amount of the NCCRP1 [31–275] fragment. In
addition, small amounts of some larger, currently unidentified 7–
10 kDa polypeptides were detected (data not shown).
Localization of NCCRP1 in HeLa cells
The subcellular localization of NCCRP1 was examined in
HeLa cells by immunocytochemistry. The protein was detected in
the cytoplasm, as shown in green in Fig. 8. In contrast, CA IX was
localized at the cell membrane, as expected (Fig. 8A and C, red).
Interestingly, these two proteins were only rarely detected in the
same cell (Fig. 8A, arrows). Control immunostaining using 30 mg
of blocking NCCRP1 recombinant protein and anti-NCCRP1
serum resulted in only very faint staining, confirming the
specificity of the antiserum (Fig. 8D). A second control using
pre-immune serum instead of the anti-NCCRP1 serum showed
virtually no staining (Fig. 8E).
Figure 6. Western blot analysis of the antibody produced
against NCCRP1. Lane 1 shows a single band confirming the
expected reactivity of the antibody towards NCCRP1 protein. The
control experiment using normal rabbit serum is negative (lane 2).
doi:10.1371/journal.pone.0027152.g006
Figure 7. Mass spectrometry analysis of NCCRP1. (A) ESI FT-ICR mass spectrum of NCCRP1 sample measured in an acetonitrile/water/acetic
acid (49.5:49.5:1.0, v/v) mixture. The sample contained an NCCPR1 [31–275] fragment (charge state 22+ denoted) and a peptide P (charge states 2+
and 3+ denoted), corresponding to the first 30 residues with an additional Gly-Ser in the N-terminus due to the used expression vector construct. The
charge-deconvoluted mass spectrum in the inset shows calculated and experimental isotopic distributions for the NCCRP1 [31–275] fragment (with
the most abundant masses indicated), as well as experimental isotopic distribution for the peptide P with a monoisotopic mass of 3260.15 Da. (B)
Primary sequence of NCCRP1. The residues corresponding to the peptide P are underlined and cysteines (Cys158, Cys192) are marked with asterisks.
doi:10.1371/journal.pone.0027152.g007
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NCCRP1 expression in human tissues
The IST database system developed by MediSapiens Ltd was
used to obtain the data for NCCRP1 mRNA expression in human
normal and cancer-derived tissues (Fig. 9A and B). The expression
pattern of NCCRP1 was relatively narrow in both normal and
cancerous tissues. The normal tissues with the highest signal were
the esophagus, oral cavity, skin, tongue and male and female
reproductive organs. The cancer-derived tissues with high
NCCRP1 expression included the squamous cell carcinoma of
the skin and cancers of the female reproductive organs.
Nccrp1 expression in mouse tissues
Nccrp1 mRNA expression was studied in several mouse tissues
by QRT-PCR. Nccrp1 transcript was expressed in all tissues
studied and the signal was highest in the kidney (Fig. 10). The
expression was moderate in the stomach, colon, duodenum and
prostate. In other tissues, Nccrp1 was expressed to a lesser degree
but signal was still clearly detectable.
The effect of growth factors and deferoxamine mesylate
on NCCRP1 mRNA expression
The influence of growth factors and deferoxamine mesylate on
NCCRP1 transcript levels was studied in HeLa cells using QRT-
PCR. The basal level of NCCRP1 expression was relatively high in
these cells and neither treatment had a major effect on its
expression. After treatment with deferoxamine mesylate, which is
commonly used to induce a hypoxia-like response, the expression
of NCCRP1 decreased moderately (1.4-fold), as shown in Fig. 11.
In contrast, deferoxamine mesylate treatment induced CA9
expression 4-fold, as expected (data not shown). Stimulation with
EGF decreased NCCRP1 expression levels but the decline was
small (1.2-fold). Other treatments did not have any effect on
NCCRP1 mRNA levels.
Expression of NCCRP1 and CA9 in human pancreatic and
breast cancer cell lines
The expression of NCCRP1 and CA9 was measured by QRT-
PCR in 16 pancreatic cancer cell lines and 21 breast cancer cell
lines. NCCRP1 showed the highest expression in the Su.86.86,
Hup-T4 and Hs700T pancreatic cancer cell lines and the MDA-
MB-415, SK-BR-3 and BT-474 breast cancer cell lines (Fig. 12).
In other cell lines, NCCRP1 was expressed at moderate or low
levels. In general, the expression of CA9 was lower than NCCRP1
in the studied cell lines. CA9 had the strongest signal in the
DU4475 breast cancer and AsPC-1 pancreatic cancer cell lines. Its
expression was moderate in a few cell lines and very low in several
others. NCCRP1 and CA9 showed reciprocal expression patterns in
some cell lines; i.e., when NCCRP1 expression was high CA9
expression was low or absent, and vice versa.
NCCRP1 and CA9 silencing
CA9 was silenced in the human glioblastoma cell line, U373,
which has a high basal level of CA9 expression. Efficient
downregulation of mRNA expression (up to 93% reduction
compared with luciferase control siRNA-treated cells) was detected
for the CA9 gene after siRNA treatment (data not shown). Silencing
of CA9 was monitored until 144 h after transfection and remained
efficient at that time point. ThemRNA level ofNCCRP1was studied
in U373 cells after CA9 silencing to examine whether NCCRP1 was
directly regulated by CA9 expression. The expression of NCCRP1
was below the detection limit of QRT-PCR at the basal level in
U373 cells and did not change after the silencing of CA9.
NCCRP1 silencing was performed in two cell lines, HeLa and
Su.86.86, and the effect of silencing on the expression level of CA9
was studied. The silencing of NCCRP1 was efficient in both cell
lines (up to 91% and 83% reduction compared with luciferase
control siRNA-treated cells for HeLa and Su.86.86 cells,
respectively). In HeLa cells, the silencing of NCCRP1 was
monitored until 144 h after transfection and remained efficient.
CA9mRNA levels were not affected by NCCRP1 silencing (Fig. 13).
The expression of CA9 steadily increased until 120 h after
transfection, after which it decreased dramatically. In Su.86.86
cells, CA9 expression was also unaffected by the silencing of
NCCRP1 (data not shown).
Effect of NCCRP1 silencing on cell growth
The effect of NCCRP1 silencing on cell growth was studied in
HeLa cells at 48, 96 and 144 h after transfection, and the analysis
was performed using ImageJ. Silencing of NCCRP1 led to a
Figure 8. Subcellular localization of NCCRP1 in HeLa cells by
immunocytochemistry. (A, B) Staining for NCCRP1 is detected in the
cytosol as shown in green. (A, C) CA IX is expressed on the cell
membrane as shown in red. (A; arrows) Only a few HeLa cells expressed
both proteins at the same time. (D) Control immunostaining using
30 mg of blocking NCCRP1 recombinant protein and anti-NCCRP1
serum together gives only a very faint staining. (E) Other control
staining using pre-immune serum instead of the anti-NCCRP1 serum
shows a barely detectable signal.
doi:10.1371/journal.pone.0027152.g008
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statistically significant decrease in HeLa cell proliferation at every
time point (Fig. 14).
Discussion
According to our previous cDNA microarray analysis, carbonic
anhydrase IX-deficient mice showed significantly upregulated
expression of Nccrp1 in the stomach, which is the most abundant
site of CA IX expression in normal mice. This finding led us to
investigate possible connections between these two genes/proteins
and to further assess the structure, regulation and function of the
NCCRP1 protein. Our bioinformatic analyses clearly linked
NCCRP1 protein to the FBXO gene family. The FBA domain
in the FBXO2, FBXO6, FBXO17 and FBXO27 proteins is a
lectin domain, and these proteins have been experimentally shown
to bind various glycans [15]. The presumed role of these proteins
is to bind misfolded and retrotranslocated glycoproteins in the
cytoplasm for ubiquitin conjugation leading to proteasomal
degradation [15]. The fact that this family of lectin-type F-box
proteins (among the dozens of different F-box proteins found in
ubiquitin ligase complexes) comprises the closest paralogs of
NCCRP1 gives us a strong reason to predict that NCCRP1
functions as a protein-binding component in ubiquitin ligase
complexes. Whether it actually binds glycans, similar to FBXO2,
FBXO6, FBXO17 and FBXO27, or lacks the ability to bind
sugar, like FBXO44 [15], remains to be tested experimentally.
However, sequence alignments and structural interpretations
(Figs. 1, 2, 3) suggest that NCCRP1 is a sixth member of the
lectin-type FBXO gene family, and we therefore propose that the
gene name be changed to FBXO50 (the number may change
based on the decision of the Human Gene Nomenclature
Committee, http://www.genenames.org/).
Jaso-Friedmann et al. [12] stated that NCCRP1 does not
contain an F-box and is therefore an exception in this subfamily.
Figure 9. Data for human NCCRP1mRNA expression from the MediSapiens database. (A) Boxplot analysis of the NCCRP1 expression levels
across healthy human tissues. (B) Boxplot analysis of the NCCRP1 expression levels across a large panel of cancer tissues. Among the normal tissues
with the highest NCCRP1 expression are the esophagus, oral cavity, skin, tongue and reproductive organs. In cancerous tissues, the expression profile
of NCCRP1 is relatively narrow, with the highest expression seen in the squamous cell carcinomas of the skin and cancers of the female reproductive
organs. The number of samples in each category is shown in parenthesis. The box refers to the quartile distribution (25–75%) range, with the median
shown as a black horizontal line. The whiskers extend to 1.5 times the interquartile range from the edges of the box, and any data points beyond this
are considered outliers and marked by open circles.
doi:10.1371/journal.pone.0027152.g009
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However, our analysis points to the existence of an F-box in
mammalian NCCRP1 proteins, and at least the remnants of one
in the fish sequences, so the name FBXO50 would be appropriate.
The ‘‘F-box associated’’ domain occurs in the human proteome
only in the six gene products discussed in this paper. This domain
could also be renamed to reflect its known functions, e.g. F-box
associated lectin(-like) domain or ubiquitin ligase lectin(-like)
domain.
To our surprise, mass spectrometry analysis indicated the
presence of a truncated protein in the NCCRP1 sample after
purification and buffer exchange, which corresponded to the
residues 31–275 of the full-length polypeptide. However, the
peptide corresponding to the first 30 residues was also detected,
which suggests that the N-terminal region had been cleaved after
the protein production, probably during purification or desalting
steps. Protein precipitation was also observed upon buffer-
exchange but it is not known whether this is related to the
observed N-terminal cleavage or change in the buffer conditions.
The reason for the intrinsically weak N-terminal region of the
NCCRP1 protein is unknown and will be investigated further.
Based on our sequence analyses, the N-terminal proline-rich
region of mammalian NCCRP1 proteins is predicted to be
disordered, which might contribute to the N-terminal truncation.
Mass analysis of the NCCRP1 [31–275] fragment also indicated
that there is an intra-molecular disulfide between Cys158 and
Cys192.
None of the NCCRP1 sequences contain any putative signal
sequences or transmembrane domains, which rules out a
membrane location. Accordingly, we showed using immunocyto-
chemistry that recombinant human NCCRP1 is expressed
intracellularly. Jaso-Friedmann, Leary and Evans previously
reported two contradictory predictions of membrane topology
and transmembrane helix location [7,8]. Both papers suggest
unrealistically short and fairly hydrophilic transmembrane helices
but provide no explanation as to how these predictions were made.
Moreover, both predictions locate the transmembrane regions in
the middle of what we now know to be the beta sandwich fold of
the FBA domain.
We speculate that the initial NCCRP1 research [7] was
hampered by an unfortunate incident of purifying and cloning
an incorrect protein with approximately the correct molecular
weight (27.3 kDa) instead of the real antigen they originally
discovered (34 kDa). In any case, our study now clearly
demonstrates that NCCRP1 is an intracellular ubiquitin ligase
protein, not a cell surface protein.
Previous reports provide some indirect results that have been
interpreted as linking fish NCCRP1 proteins with cytotoxicity.
First, NCCRP1 anti-sense oligonucleotides were found to reduce
the cytotoxicity of catfish NCC cells [7]. In our study, we have
demonstrated the anti-proliferative effect of siRNA-mediated
NCCRP1 knockdown in HeLa cells, which may be due to a failure
to degrade misfolded glycoproteins. We hypothesize that similar
disturbances in viability or in protein secretion could account for
the effect of anti-sense oligonucleotides in catfish NCC cells.
Second, peptides derived from catfish and zebrafish NCCRP1
were observed to reduce NCC-mediated cell lysis [8,12]. These
peptides (Figs. 1 and 4) come from the most highly conserved
region of the lectin domain and contain amphiphilic beta strands.
We believe that the hydrophobic patches in these peptides would
have a high degree of nonspecific binding and could interfere with
various cell surface events. The uniform orientation of hydropho-
bic residues is sequence-dependent and would be lost in most
randomized peptides, which may have been the case in a previous
report [12], leading to seemingly specific results for a peptide that
is not derived from a cell-surface receptor.
The human lectin-type F-box-only (FBXO) genes are present in
two clusters in the genome: FBXO2, FBXO6 and FBXO44 on
chromosome 1, and FBXO17 and FBXO27 on chromosome 19.
NCCRP1 is only 150 kb away from FBXO27, separated by two
other genes. The adjacent gene triplet on human chromosome 1
Figure 10. The Nccrp1 mRNA expression in mouse tissues by
QRT-PCR. Nccrp1 is present in all the tissues studied. The expression of
Nccrp1 is highest in the kidney and moderate in the stomach, colon,
duodenum and prostate. In the other tissues Nccrp1 expression is
modest. Normalized median values calculated from the technical
triplicates are shown.
doi:10.1371/journal.pone.0027152.g010
Figure 11. The effect of different treatments on NCCRP1 levels
in HeLa cells. The treatments included deferoxamine mesylate (DFM),
transforming growth factor-alpha (TGF-a), transforming growth factor-
beta 1 (TGF-b1) and epidermal growth factor (EGF). Deferoxamine
mesylate and EGF treatments moderately decreased the expression of
NCCRP1 (1.4-fold and 1.2-fold, respectively). The normalized values of
triplicate experiments as detected by QRT-PCR are shown.
doi:10.1371/journal.pone.0027152.g011
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and the pair on chromosome 19 are likely due to recent gene
duplication events. However, the phylogenetic tree in Fig. 2B
indicates that FBXO17 and FBXO27 share their latest common
ancestor with the triplet of FBXO genes on chromosome 1, and
therefore, their proximity to NCCRP1 may be coincidental. A full
phylogenetic analysis of FBXO proteins and their emergence in
various vertebrate taxa would be an interesting topic for a future
study.
Because there have been no previous reports on the expression
pattern of NCCRP1 in mammals, we examined mRNA levels of
human and mouse NCCRP1. In normal human tissues, NCCRP1 is
strongly confined to the squamous epithelium, mainly being
detected in tissues such as the esophagus, oral cavity, skin and
tongue. The expression pattern is similar in cancerous tissues; the
highest expression was seen in squamous cell carcinomas of the
skin, cervix and vagina/vulva. In mice, the expression of Nccrp1
was highest in the kidney and moderate in the stomach, colon,
duodenum and prostate. Lower levels of the transcript were also
detectable in the other tissues studied, including the parotid and
submandibular glands, lung, jejunum, ileum and testis. These data
suggest that NCCRP1 is relatively ubiquitously expressed, similar
to FBXO6, FBXO27 and FBXO44 [15]. In contrast, FBXO2 is
predominantly expressed in different areas of the brain and only
weakly in some other tissues [15,18], and FBXO17 is expressed in
only a few tissues [15,18]. It should be noted that many tissues
express several FBXO genes. For example, major glycoprotein-
producing tissues include the brain, liver and pancreas, all of
which express multiple FBXO family members [15]. In this
Figure 12. Screening of NCCRP1 and CA9mRNA expression in cancer cell lines. 16 human pancreatic (AsPC-1 to SW 1990) and 21 breast (BT-
474 to ZR-75-30) cancer cell lines were screened using QRT-PCR. The expression of NCCRP1 is highest in the Su.86.86, Hup-T4 and Hs700T pancreatic
cancer cell lines and the MDA-MB-415, SK-BR-3 and BT-474 breast cancer cell lines. CA9 is most highly expressed in the DU4475 breast cancer and
AsPC-1 pancreatic cancer cell lines. The expression levels of these genes typically show a reciprocal pattern: high simultaneous expression is observed
in none of these cell lines. The normalized values are shown.
doi:10.1371/journal.pone.0027152.g012
Figure 13. CA9 expression after silencing of NCCRP1 in HeLa
cells. The mRNA expression of CA9 was monitored for 144 h after the
silencing of NCCRP1. No change was observed in CA9 expression with
NCCRP1 siRNA compared with luciferase (Luc) control siRNA. The
normalized median values calculated from the three replicates are
shown.
doi:10.1371/journal.pone.0027152.g013
Figure 14. The effect of NCCRP1 silencing on cell proliferation in
HeLa cells as analyzed by ImageJ. Cell growth was studied at 48, 96
and 144 h after transfection. The silencing of NCCRP1 caused a
statistically significant decrease in cell proliferation at every time point.
Statistically significant differences relative to luciferase (Luc) control
siRNA were determined. ** p,0.01.
doi:10.1371/journal.pone.0027152.g014
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respect, the expression pattern of NCCRP1 in human tissues is
exceptional because it is almost solely present in tissues containing
squamous epithelium. On the other hand, Nccrp1 is expressed
widely in mouse tissues; this pattern resembles the expression of
other ubiquitously expressed FBXO genes.
Finally, we examined the connection between CA9 and NCCRP1
using several different approaches. Nccrp1 was originally found to
be significantly upregulated in the gastric mucosa of CA IX-
deficient mice [6], which prompted us to explore its role more
closely, but focusing on the human gene. In HeLa cells, we found
that the NCCRP1 and CA IX proteins usually ‘‘avoid’’ each other;
that is, they are only rarely expressed in the same cells (Fig. 8A,
arrows). Furthermore, in a panel of 16 pancreatic cancer cell lines
and 21 breast cancer cell lines, NCCRP1 and CA9 expression were
inversely correlated in certain cell lines; NCCRP1 was weakly
expressed or absent when CA9 mRNA was highly expressed, and
vice versa. These data support the observation in Car9 knockout
mice in which the expression of Nccrp1 was increased in the
absence of Car9. We also determined whether the expression of
NCCRP1 was regulated in a similar manner to CA9 in HeLa cells.
NCCRP1 expression decreased moderately after stimulation with
deferoxamine mesylate, which was used to induce a hypoxia-like
response. On the contrary, CA9 expression increased highly, as
expected. Thus, NCCRP1 does not seem to share a main
regulatory pathway with CA IX.
siRNA-mediated gene silencing was used to study whether CA9
expression directly regulates NCCRP1 expression. Knockdown of
CA9 in U373 cells had no effect on NCCRP1 expression levels,
implying that NCCRP1 is not directly regulated by CA9, at least in
this cell line. Likewise, silencing of NCCRP1 in HeLa and Su.86.86
cells did not affect CA9 expression. Interestingly, we found that
knockdown of NCCRP1 led to a statistically significant decrease in
the growth of HeLa cells, and this effect was still observed at 144 h
after transfection. FBXO6 has also been shown to promote growth
and proliferation of gastric cancer cells compared with control cells
that do not express the protein [19]. One plausible explanation for
these observations is that NCCRP1 and FBXO6 are needed to
target certain glycoproteins that affect the cell cycle for
degradation and that the proliferation of cancer cells is impaired
when this function is inhibited. The results of this study indicate
that NCCRP1 is not directly regulated by CA9, but there are more
complicated regulation events that lead to its upregulation when
CA9 is knocked down.
In conclusion, these studies provide ample evidence that the
present name, ‘‘non-specific cytotoxic cell receptor protein 1,’’
does not fittingly describe the polypeptide known as NCCRP1.
Bioinformatic analyses clearly show that NCCRP1 is a paralog to
five other FBXO genes. We have also shown experimentally that
the human recombinant NCCRP1 protein is expressed in the
cytosol, not on the cell surface. Furthermore, the tissue expression
pattern of NCCRP1 in humans and mice is incompatible with an
immune receptor function.
Materials and Methods
Bioinformatics
Sequences were retrieved from Ensembl release 62 (www.
ensembl.org) [20], UniProt (www.uniprot.org) [21], GenBank
(www.ncbi.nlm.nih.gov/genbank/) [22] and RefSeq (www.ncbi.
nlm.nih.gov/RefSeq/) [23]. BLAST searches were carried out via
NCBI (blast.ncbi.nlm.nih.gov/Blast.cgi) [24]. Multiple sequence
alignments were prepared with ClustalW (www.ebi.ac.uk/Tools/
msa/clustalw2/) [25] and Mafft (www.ebi.ac.uk/Tools/msa/
mafft/) [26] and visualized with GeneDoc (www.nrbsc.org/gfx/
genedoc/). Protein motifs were searched using InterProScan
(www.ebi.ac.uk/Tools/pfa/iprscan/) [27] and transmembrane
domains were predicted with TMHMM v. 2.0 (www.cbs.dtu.dk/
services/TMHMM/) [28]. Signal peptides and other target
peptides were predicted using SignalP 3.0 with eukaryotic
parameters (www.cbs.dtu.dk/services/SignalP/) [28] and TargetP
1.1. with non-plant parameters (www.cbs.dtu.dk/services/Tar-
getP/) [28], respectively. Intrinsic protein disorder was predicted
with DISpro (www.ics.uci.edu/,baldig/dispro.html) [29]. Phylo-
genetic trees were prepared using the MEGA4 software (www.
megasoftware.net/) [30] with maximum parsimony and the
complete deletion option for gapped sites with 1000 bootstrap
replicates. Molecular images were prepared with PyMol 0.99
(DeLano Scientific, South San Francisco, CA).
Construction of recombinant human NCCRP1
The full-length protein-coding cDNA sequence for human
NCCRP1 was obtained from the Mammalian Gene Collection,
and the cDNA clone (IMAGE ID: 30348184) was purchased from
Source BioScience LifeSciences (Cambridge, United Kingdom).
Plasmid DNA was isolated from an overnight culture using a
QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany). NCCRP1
cDNA was amplified by PCR using PhusionTM Hot Start High
Fidelity DNA Polymerase (Finnzymes, Espoo, Finland). Primers
were ordered from Biomers (Ulm, Germany). The forward primer
sequence was 59-CCG CGG ATC CAT GGA GGA GGT GCG
TGA GGG A-39 and the reverse primer was 59-CGC CGT CGA
CTC ACT CCC GGA GCT GCA CAG-39, with the restriction
sites for BamHI and SalI underlined, respectively. PCR was
performed in an XP Thermal Cycler (Bioer Technology,
Hangzhou, China) with a program consisting of a single 98uC
denaturation step for 30 s followed by 35 cycles of denaturation at
98uC for 10 s, annealing at 64uC for 30 s and extension at 72uC
for 30 s, and a final extension at 72uC for 5 min. The PCR
product band was separated from agarose gel and dissolved using
an IllustraTM GFX PCR DNA and GEL Band Purification Kit
(GE Healthcare Life Sciences, Buckinghamshire, UK). The
purified PCR product and pGEX-4T-1 vector (Invitrogen,
Carlsbad, CA) were digested at 37uC for 2 hours with the BamHI
and SalI restriction enzymes (New England Biolabs, Ipswich, MA,
USA). The digested plasmid and NCCRP1 construct were purified
and ligated overnight at 4uC using T4 DNA ligase (New England
Biolabs). The ligated product was transformed into E. coli
BL21(DE3)pLysS bacteria (Promega, Madison, WI, USA).
Overnight cultures (5 ml) were grown from colonies, and plasmids
were purified using a QIAprep Spin Miniprep KitTM (Qiagen).
Sequencing was performed to verify the sequence of the NCCRP1
construct. This purification method was based on a glutathione S-
transferase (GST) gene fusion system. Expression of pGEX-4T-1
in E. coli yielded fusion proteins with the GST moiety at the amino
terminus and NCCRP1 recombinant protein at the carboxyl
terminus. The construct also contained a thrombin protease site
between the GST tag and NCCRP1. This vector construct codes
additional Gly and Ser residues to the N-terminus of the
recombinant protein.
Production and purification of recombinant human
NCCRP1
A single BL21(DE3)pLysS transformant colony was grown in
5 ml LB medium containing 50 mg/ml ampicillin at room
temperature with shaking (200 rpm) overnight and used to
inoculate 500 ml of LB/amp medium. This culture was grown
until the optical density (OD) at 600 nm reached 0.6. Expression
of NCCRP1 protein was induced by adding isopropyl b-D-1-
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thiogalactopyranoside (IPTG) (Fermentas, Ontario, Canada) at a
final concentration of 0.25 mM, and the culture was grown at
room temperature overnight. The cells were harvested by
centrifugation (Sorvall RC 28S) at 5,000 rpm for 5 min at room
temperature. The cell pellet was suspended in 10 ml Tris-buffer
containing 0.1 M Tris-Cl, pH 8, 0.05% Triton X-100, 200 mg
lysozyme, 200 U DNase (Roche, Penzberg, Germany) and the
protease inhibitors phenylmethanesulfonylfluoride (0.2 mg; Sig-
ma-Aldrich, Helsinki, Finland) and leupeptin (0.1 mg) (Santa
Cruz, Heidelberg, Germany). After a 30-min incubation at room
temperature, the cell suspension was placed on ice and sonicated
for 1 min. The suspension was clarified by centrifugation at
10,000 rpm for 30 min at 4uC, and the clear supernatant was
affinity purified using Glutathione Sepharose 4B medium (GE
Healthcare, Buckinghamshire, UK). Recombinant NCCRP1
protein was isolated under native conditions according to the
manufacturer’s protocol. A site-specific thrombin (GE Healthcare)
was used for specific cleavage of the GST under shaking at room
temperature overnight. Finally, the protein was eluted using the
glutathione elution method (GE Healthcare) recommended by the
manufacturer. The size of the expressed NCCRP1 protein was
determined under reducing conditions by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
Production of a polyclonal antibody and western blotting
Anti-human NCCRP1 serum was raised in a rabbit against the
purified full-length NCCRP1 by Innovagen AB (Lund, Sweden).
Western blotting was used to confirm the reactivity of the antibody
with NCCRP1.
Recombinant NCCRP1 proteins were subjected to SDS-PAGE
under reducing conditions and transferred to polyvinylidene
fluoride (PVDF) membranes. The membranes were treated with
blocking solution (Santa Cruz, Heidelberg, Germany) for 30 min.
After blocking, the membrane was incubated with the primary
antibody (rabbit anti-NCCRP1) diluted 1:2,000, or normal rabbit
serum as a control, and washed. The membrane was incubated
with the secondary antibody diluted 1:25,000 (anti-rabbit Ig,
horseradish-peroxidase-linked whole antibody from donkey,
Amersham Biosciences, Buckinghamshire, England) and washed,
and protein bands were visualized by electrochemiluminescence
(ECL) using Amersham ECLTM Western Blotting Detection
Reagents (GE Healthcare) according to the manufacturer’s
instructions.
Mass spectrometry
All experiments were performed on a 4.7-T Fourier transform
ion cyclotron resonance (FT-ICR) mass spectrometer (APEX-Qe;
Bruker Daltonics, Billerica, MA, USA) equipped with an Apollo-II
ion source and a mass-selective quadrupole front-end. This
instrument has been described in detail elsewhere [31]. The
protein samples were buffer exchanged into 10 mM ammonium
acetate buffer, pH 6.9, on PD-10 columns (Amersham Bioscienc-
es, Billingham, UK) and directly electrosprayed at a flow rate of
1.5 mL/min. ESI-generated ions were externally accumulated for
1 s in a hexapole ion trap and transmitted to the ICR for trapping,
excitation and detection. For each spectrum, 1,000 co-added 512-
kWord time-domain transients were recorded, zero-filled twice,
Gaussian multiplied and fast Fourier transformed before magni-
tude calculation and external mass calibration with respect to the
ions of an ES Tuning Mix (Agilent Technologies, Santa Clara,
CA, USA). All data were acquired and processed using Bruker
XMASS 6.0.2 software. Mass spectra were further charge
deconvoluted using a standard deconvolution macro implemented
in the XMASS software. Tryptic digests were obtained by
dissolving a small amount of the protein precipitate in 100 ml of
a 10 mM ammonium bicarbonate buffer, pH 8.5, and 15 mg of
sequencing grade trypsin (Promega GmbH, Mannheim, Germany)
in 15 ml of water was added. The digest sample was incubated at
37uC for 1.5 hours, after which no precipitate was observed, and
the sample was directly analyzed without chromatographic
separation. The resulting protein or peptide masses were matched
against the protein sequence using the GPMAW 8.11 software,
and tryptic peptide masses were further subjected to database
search using the Mascot search engine (www.matrixscience.com).
Cell lines
A panel of 16 established pancreatic cancer cell lines was used in
this study. Thirteen of these (AsPC-1, BxPC-3, Capan-1, Capan-2,
CFPAC-1, HPAC, HPAF-II, Hs 700T, Hs 766T, MIA PaCa-2,
PANC-1, Su.86.86, and SW 1990) were purchased from the
American Type Culture Collection (ATCC, Manassas, VA, USA),
and three (DanG, Hup-T3, and Hup-T4) were purchased from the
German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany). The 21 breast cancer cell lines used
in this study (BT-474, CAMA-1, DU4475, HCC38, HCC1419,
HCC1954, MCF7,MDA-MB-134-VI, MDA-MB-231, MDA-MB-
361, MDA-MB-415, MDA-MB-436, MDA-MB-453, SK-BR-3,
T-47D, UACC-732, UACC-812, UACC-893, UACC-3133, ZR-
75-1, and ZR-75-30) were obtained from the ATCC. The U373
human glioblastoma astrocytoma cell line was purchased from the
European Collection of Cell Cultures. The HeLa human cervical
carcinoma cell line was from the laboratory of Professor Jorma
Isola (Institute of Biomedical Technology, University of Tampere,
Tampere, Finland). Cells were grown under the recommended
culture conditions.
Immunocytochemistry
Rabbit anti-human NCCRP1 serum (Innovagen) and the M75
antibody specific for the PG region of CA IX were used for
immunocytochemistry [32]. Non-immune normal rabbit serum
was used as a control.
HeLa cells were fixed with 4% (vol/vol) neutral-buffered
formaldehyde for 30 min. The cells were then rinsed with PBS
and subjected to immunofluorescence staining using the following
protocol: (a) pre-treatment with 0.1% BSA in PBS (BSA-PBS) for
30 min; (b) incubation for 1 h with rabbit NCCRP1 antiserum or
normal rabbit serum diluted 1:100 in 0.1% BSA-PBS or mouse
CA IX antiserum diluted 1:10 in 0.1% BSA-PBS; (c) rinsing three
times for 5 min with BSA-PBS; (d) incubation for 1 h with 1:100
diluted Alexa Fluor 488 goat anti-rabbit IgG antibodies or Alexa
Fluor 568 goat anti-mouse IgG antibodies (both from Molecular
Probes, Eugene, Oregon, USA) in 0.1% BSA-PBS; (e) rinsing two
times for 5 min with BSA-PBS and once with PBS. All incubations
and washings were performed in the presence of 0.05% saponin.
Immunostained cells were analyzed and photographed using a
Zeiss LSM 700 confocal laser scanning microscope.
NCCRP1 expression in human and mouse tissues
NCCRP1 mRNA expression levels across a large number of
human tissues were retrieved from the IST database system
developed by MediSapiens Ltd. The current version of the IST
database (4.3) contains 20,218 human tissue and cell line samples
analyzed by Affymetrix gene expression microarrays. The
database was constructed and validated using methods similar to
those described by Kilpinen et al. [33] and Autio et al. [34] for the
construction of the GeneSapiens database. The database contains
expression data that is fully integrated in terms of both the
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annotation and numerical compatibility, allowing for analysis of
the expression levels of 19,123 genes across 228 distinct tissues.
Mouse tissues were obtained from C57BL/6 mice that were
maintained in the animal facility of the University of Oulu. A total
of six mice (3 males and 3 females) were sacrificed at two months
of age. Tissue specimens were taken from the following areas:
parotid gland, submandibular gland, stomach, duodenum, jeju-
num, ileum, colon, lung, kidney, prostate and testis. The tissue
samples were immediately immersed in RNAlater solution
(Ambion, Austin, TX, USA) and frozen at 280uC.
Total RNA was extracted from the mouse tissues using an
RNeasy RNA isolation kit (Qiagen, Valencia, USA) following the
manufacturer’s instructions. Residual DNA was removed from the
samples using RNase-free DNase (Qiagen). The RNA concentra-
tion and purity was determined by measuring the optical density at
260 and 280 nm. Different quantities of RNA (lung and prostate:
200 ng, ileum: 900 ng, all other tissues: 2,000 ng) were converted
into first strand cDNA using a First Strand cDNA synthesis kit
(Fermentas, Burlington, Canada) with random hexamer primers
according to the manufacturer’s protocol.
The relative expression levels of the mouse Nccrp1 gene in
several tissues were assessed by quantitative real-time PCR (QRT-
PCR) using the LightCycler detection system (Roche, Rotkreuz,
Switzerland). The primers (Table 2) were designed using Primer3
(http://frodo.wi.mit.edu/primer3/) and based on the complete
cDNA sequence deposited in GenBank. The specificity of the
primers was verified using NCBI Basic Local Alignment Search
Tool (BLAST) (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The
housekeeping gene b-actin (Actb) was used as internal control to
normalize the cDNA samples for possible differences in quality
and quantity (Table 2).
Each PCR reaction was performed in a total volume of 20 ml
containing 1.0 ml of first strand cDNA, 16 QuantiTect SYBR
Green PCRMaster Mix (Qiagen, Hilden, Germany) and 0.5 mM of
each primer. Amplification and detection were conducted as
follows: after an initial 15 min activation step at 95uC, amplification
was performed in a three-step cycling procedure for 45 cycles
consisting of denaturation at 95uC for 15 s, annealing at a
temperature determined according to the Tm for each primer pair
for 20 s, and elongation at 72uC for 15 s (the ramp rate was 20uC/s
for all the steps), and a final cooling step was performed. Melting
curve analysis was always performed after the amplification to check
the specificity of the PCR reaction. To quantify the levels of
transcripts in the cell lines studied, a standard curve was established
for each gene using five-fold serial dilutions of known concentrations
of purified PCR products generated with the same primer pairs.
Each cDNA sample was tested in triplicate, and the crossing point
(Cp) value obtained allowed the levels of the starting mRNA to be
determined using a specific standard curve. The relative mRNA
expression was calculated as the copy number of the target gene
divided by the corresponding normalization factor and multiplied
by 103. Median values were calculated from the technical triplicates.
The effect of growth factors and deferoxamine mesylate
on mRNA expression of NCCRP1
HeLa cells were grown in 75 cm2 flasks in a 37uC incubator
with humidified 5% CO2/95% air. When the cultured cells
reached 80–90% confluence, they were trypsinized and plated in
58 cm2 dishes at a density of 1 million cells per dish. After
24 hours, the medium was replaced with fresh medium containing
recombinant human transforming growth factor-alpha (TGF-a;
10 ng/ml), recombinant human transforming growth factor-beta 1
(TGF-b1; 10 ng/ml), recombinant human epidermal growth
factor (EGF; 10 ng/ml), or deferoxamine mesylate (200 mM), an
iron chelator commonly used to induce the hypoxia regulatory
pathway. Normal medium was added to control plates. TGF-b1
and EGF were purchased from ProSpec-Tany TechnoGene Ltd.
(Rehovot, Israel). TGF-a was purchased from PromoCell GmbH
(Heidelberg, Germany). Deferoxamine mesylate was obtained
from Sigma-Aldrich Finland Oy (Helsinki, Finland). The chem-
icals were diluted as necessary according to the manufacturers’
instructions. The cells were incubated for 72 hours, after which
they were harvested and total RNA was extracted using an
RNeasy RNA isolation kit. For each sample, 850 ng of RNA
was converted into first strand cDNA by reverse transcription
and QRT-PCR was performed as described above. The primers
for human NCCRP1 and CA9 were designed using Primer3 and
the primers for the housekeeping gene ubiquitin C (UBC)
were obtained from the RTprimerDB database (http://www.
rtprimerdb.org/) under the identification number 8 (Table 2). The
median values were calculated from the technical triplicates for the
QRT-PCR experiments. Subsequently, the median values for
treatments were compared to the median values for negative
controls.
Table 2. QRT-PCR primer sequences used in this study.
Gene symbol Description GenBank number Forward primer (59-39) Reverse primer (59-39)
Nccrp1 Mus musculus non-specific
cytotoxic cell receptor
protein 1
homolog(zebrafish)
NM_001081115 GCTGCATGTCTGGCTGTTAG ATGCGGTTCTTAGCCTTGTG
Actb Mus musculus actin, beta NM_007393 AGAGGGAAATCGTGCGTGAC CAATAGTGATGACCTGGCCGT
NCCRP1 Homo sapiens non-specific
cytotoxic cell receptor
protein 1
homolog(zebrafish)
NM_001001414 TTCCGTGGCTGGTACATTAG ATGGCTGGTTGTTCGTCATC
CA9 Homo sapiens carbonic
anhydrase IX
NM_001216 ATGAGAAGGCAGCACAGAAG TAATGAGCAGGACAGGACAG
UBC Homo sapiens ubiquitin C NM_021009 ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT
GAPDH Homo sapiens
glyceraldehyde-3-
phosphate dehydrogenase
NM_002046 TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG
doi:10.1371/journal.pone.0027152.t002
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Expression of CA9 and NCCRP1 in human pancreatic and
breast cancer cell lines
To examine the co-expression of human CA9 and NCCRP1 in
tumor cells, transcript levels were measured in 16 pancreatic and
21 breast cancer cell lines using QRT-PCR. Total RNA was
isolated from the cell lines using TRIzol reagent (Invitrogen,
Carlsbad, CA), and 5 mg of each RNA sample was converted into
first strand cDNA using SuperScript III First-Strand Synthesis kit
(Invitrogen) according to the manufacturer’s instructions. QRT-
PCR reactions were performed as described above, with the
exception that each cDNA sample was tested only once. The
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a reference (Table 2). The final relative
mRNA expression was calculated as the copy number of the target
gene divided by the corresponding normalization factor, multi-
plied by 104.
NCCRP1 and CA9 silencing
The human NCCRP1 and CA9 genes were silenced using specific
ON-TARGETplus SMARTpool small interfering RNAs (siRNAs)
(Thermo Fisher Scientific, Lafayette, CO). The catalog numbers
for NCCRP1 and CA9 SMARTpools are L-032307-01-0005 and L-
005244-00-0005, respectively. U373 cells, HeLa cells and
Su.86.86 cells were transfected with the siRNAs using INTER-
FERinTM reagent (PolyPlus-transfection, Illkirch, France) accord-
ing to the manufacturer’s instructions. Transfections were
performed in 24-well plates with the desired cell density (25,000
cells per well for U373 and HeLa cells and 50,000 cells per well for
Su.86.86 cells). Final concentrations of 10 nM for CA9 siRNA and
30 nM for NCCRP1 siRNA were used. Parallel control experi-
ments using siRNA targeting the firefly luciferase (PPYLUC) gene
were also performed. The sequence of the PPYLUC siRNA was 59-
GAUUUCGAGUCGUCUUAAUTT-39. All siRNA experiments
were performed in triplicate and repeated twice. Gene silencing
was verified each time using QRT-PCR as described above. The
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a reference (Table 2). Median values were
calculated from the triplicate QRT-PCR experiments, and the
median values for NCCRP1 or CA9 siRNA-treated cells were
compared to the median values for luciferase control siRNA-treated
cells to estimate the efficacy of silencing.
Cell growth analyses
For cell growth analyses, 15,000 HeLa cells per well were
transfected with NCCRP1 SMARTpool siRNAs or luciferase control
siRNA as described above. Cell growth was analyzed at 48, 96,
and 144 hours after transfection.
From each well, 464 fields were photographed using Olympus
IX71 microscope with a 1006 objective. Quantitative analysis of
the captured images was performed using the public domain
image processing software ImageJ (http://rsbweb.nih.gov/ij/). A
custom-made algorithm was developed for the analysis; it first
identified the cellular area of the sample image at each time point
and then measured the relative change in the cellular area
percentage over the sample-specific time course.
Statistical analyses
For the cell growth analyses, the Mann-Whitney test was used to
evaluate differences in group values for NCCRP1 SMARTpool
siRNA-treated HeLa cells vs. luciferase control siRNA-treated HeLa
cells.
Ethics statement
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